Leonteq Securities AG Has $63,000 Holdings in Tilray Brands, Inc. $TLRY

Leonteq Securities AG trimmed its position in Tilray Brands, Inc. (NASDAQ:TLRY) by 97.6% in the first quarter, according to its most recent filing with the SEC. The fund owned 9,737 shares of the company’s stock after selling 396,951 shares during the period. Leonteq Securities AG’s holdings in Tilray Brands were worth $63,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Tudor Investment Corp ET AL bought a new stake in Tilray Brands during the 3rd quarter worth $518,000. Cresset Asset Management LLC raised its position in Tilray Brands by 72.1% in the third quarter. Cresset Asset Management LLC now owns 501,989 shares of the company’s stock valued at $868,000 after purchasing an additional 210,267 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in Tilray Brands by 99,204,800.0% in the third quarter. Caitong International Asset Management Co. Ltd now owns 992,049 shares of the company’s stock valued at $1,716,000 after purchasing an additional 992,048 shares during the last quarter. Zuckerman Investment Group LLC acquired a new stake in shares of Tilray Brands during the third quarter valued at about $147,000. Finally, Hillsdale Investment Management Inc. acquired a new stake in shares of Tilray Brands during the fourth quarter valued at about $4,855,000. Institutional investors and hedge funds own 9.35% of the company’s stock.

Insider Activity

In other news, Director David G. Hopkinson sold 33,556 shares of the business’s stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an average price of $6.94, for a total value of $232,878.64. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on TLRY. Roth Capital raised Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a research note on Thursday, April 2nd. TD Cowen dropped their price objective on shares of Tilray Brands from $10.00 to $7.00 and set a “buy” rating for the company in a report on Monday, March 30th. Wall Street Zen upgraded shares of Tilray Brands from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Weiss Ratings lowered shares of Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Finally, ATB Cormark Capital Markets decreased their price target on shares of Tilray Brands from $9.50 to $9.00 and set a “sector perform” rating for the company in a research report on Thursday, April 2nd. Three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Tilray Brands presently has an average rating of “Hold” and an average target price of $11.50.

Tilray Brands Stock Performance

Shares of TLRY stock opened at $4.37 on Thursday. The stock has a market capitalization of $509.32 million, a PE ratio of -0.32 and a beta of 1.89. The business’s 50 day simple moving average is $5.14 and its 200 day simple moving average is $6.88. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.79 and a quick ratio of 1.66. Tilray Brands, Inc. has a one year low of $4.20 and a one year high of $23.20.

Tilray Brands Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.